Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chetachi Akunna Otele
Observed name:
C. Akunna Otele
Institution:
Regeneron (United States)
Observed institution:
Regeneron (United States)
OpenAlex ID:
A5115022633
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM‐2 study
2026
·
Stefano Luminari
, Ana Jiménez‐Ubieto
, et al.
·
HemaSphere
·
1
Linvoseltamab (LINVO) in Frail Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the LINKER-MM1 Study
2025
·
Hira Mian
, Naresh Bumma
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study
2024
·
Sabarish Ayyappan
, H. Miles Prince
, et al.
·
Blood
·
1
PDF
Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study
2024
·
Stefano Luminari
, Jose C. Villasboas Bisneto
, et al.
·
Blood
·
1
PDF
Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study
2026
·
Joshua Richter
, Madhav Dhodapkar
, et al.
·
Blood Cancer Journal
PDF
Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study
2026
·
Hira Mian
, Naresh Bumma
, et al.
·
Blood Cancer Journal
PDF
IBCL-684: Clinical Outcomes According to Baseline Comorbidities and Age in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Treated With the Bispecific Antibody (bsAb) Odronextamab in the Phase 2 ELM-2 Study
2025
·
Jason Westin
, Chetachi Akunna Otele
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
IBCL-576: Long-Term Follow-Up of the Phase 2 ELM-2 Study: Efficacy and Survival Outcomes With Odronextamab in Relapsed/Refractory Follicular Lymphoma
2025
·
Gottfried von Keudell
, Deepa Jagadeesh
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-576 Long-Term Follow-Up of the Phase 2 ELM-2 Study: Efficacy and Survival Outcomes With Odronextamab in Relapsed/Refractory Follicular Lymphoma
2025
·
Gottfried von Keudell
, Deepa Jagadeesh
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-684 Clinical Outcomes According to Baseline Comorbidities and Age in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Treated With the Bispecific Antibody (bsAb) Odronextamab in the Phase 2 ELM-2 Study
2025
·
Jason Westin
, Chetachi Akunna Otele
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
10
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type
